Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 6, 2021
Reporting Period: Event-based (July 6, 2021 transaction)
The Company entered into Securities Purchase Agreements (SPAs) and Registration Rights Agreements (RRAs) with three pre-existing investors to raise capital through a private placement of common stock.
Key Financial Metrics
Capital Raised: Aggregate investment of $5,000,000.
Shares Issued/To Be Issued: 1,666,667 shares of common stock.
Purchase Price: $3.00 per share.
Investors: Bespoke Growth Partners, Inc., Keystone Capital Partners, LLC, and Richard Gilliam.
Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a transaction report, not a periodic financial statement.
Material Changes and Transaction Details
- Investment Structure: The transaction is structured in two tranches: an initial closing and a subsequent closing contingent upon the effectiveness of a Registration Statement.
- Initial Closing (July 6, 2021):
- Bespoke: Purchased 83,334 shares ($250,002).
- Keystone: Purchased 50,000 shares ($150,000).
- Gilliam: Purchased 33,334 shares ($100,002).
- Subsequent Closing (Upon Registration Effectiveness):
- Bespoke: Agreed to purchase an additional 750,000 shares ($2,250,000).
- Keystone: Agreed to purchase an additional 450,000 shares ($1,350,000).
- Gilliam: Agreed to purchase an additional 300,000 shares ($900,000).
- Registration Rights: The Company is obligated to file a registration statement within 30 days of the agreement and use commercially reasonable efforts to have it declared effective within 30 days of filing (or 60 days in the event of a full SEC review).
Guidance, Risks, and Unusual Items
Regulatory Status: The shares were sold pursuant to an exemption from registration requirements under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. The shares are not registered and may not be offered or sold in the U.S. absent an effective registration statement or exemption.
Related Party Transactions: One investor, Bespoke Growth Partners, Inc., is controlled by Mark Peikin, the Company's Chief Strategy Officer.
Outlook: The filing does not contain specific financial guidance or management commentary regarding future operational performance beyond the capital raise.
Investor Verification Checklist
- Verify the effectiveness of the Registration Statement to confirm the release of the remaining $3,750,000 in committed capital.
- Review the impact of the 1,666,667 new shares on existing shareholder dilution.
- Confirm the status of the related-party transaction involving the Chief Strategy Officer's controlled entity.
- Check subsequent filings for the actual date the Registration Statement was declared effective by the SEC.